Neville Rodie & Shaw’s Acadia Pharmaceuticals ACAD Stock Holding History

Neville Rodie & Shaw’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,000	Closed	-$802K	–	258
2020 Q4	$802K	Hold	15,000	–	–	0.07%	134
2020 Q3	$619K	Hold	15,000	–	–	0.06%	146
2020 Q2	$727K	Hold	15,000	–	–	0.08%	129
2020 Q1	$634K	Hold	15,000	–	–	0.08%	131
2019 Q4	$642K	Hold	15,000	–	–	0.06%	154
2019 Q3	$540K	Hold	15,000	–	–	0.06%	166
2019 Q2	$401K	Hold	15,000	–	–	0.04%	185
2019 Q1	$403K	Hold	15,000	–	–	0.04%	188
2018 Q4	$243K	Hold	15,000	–	–	0.03%	209
2018 Q3	$311K	Hold	15,000	–	–	0.03%	204
2018 Q2	$229K	Buy	+15,000	New	+$267K	0.02%	231

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Neville Rodie & Shaw's ACAD Position: Q1 2021 in Review

Neville Rodie & Shaw sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 15,000 shares — an estimated $802K sold.

Neville Rodie & Shaw first reported a position in ACAD in Q2 2018 and held it in 11 quarters. The position peaked at $802K in Q4 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

Neville Rodie & Shaw reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Neville Rodie & Shaw sold 15,000 Acadia Pharmaceuticals shares in Q1 2021, an estimated $802K.
Neville Rodie & Shaw first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 11 quarters.
Neville Rodie & Shaw's Acadia Pharmaceuticals position peaked at $802K in Q4 2020.
272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Neville Rodie & Shaw's 13F filing for Q1 2021, filed 8 Apr 2021.